Pfizer Plan for COVID Vaccine Series for Babies of 6 Months Draws Fierce Controversy

closeup of a baby

Pfizer announced last week the Food and Drug Administration (FDA) had asked the drug company, and its partner BioNTech, to submit data on a COVID vaccine series for babies as young as 6 months old.

Albert Bourla, chairman and CEO of Pfizer, said in the statement:

As hospitalizations of children under 5 due to COVID-19 have soared, our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus. Ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection against current and potential future variants. If two doses are authorized, parents will have the opportunity to begin a COVID-19 vaccination series for their children while awaiting potential authorization of a third dose.

Read More

Top Cardiologist: Vaccine-Induced Myocarditis in Young People ‘Way More Serious’ Than COVID-Induced Myocarditis

Dr. Peter McCullough, a top cardiologist and leader in the medical response to the COVID pandemic, said in a recent interview that myocarditis in young people post vaccine is far more dangerous than the COVID version of the heart disease.

Cases of myocarditis—inflammation of the heart muscle—have spiked dramatically among previously healthy people in heavily vaccinated countries. Health officials have maintained that vaccine-induced myocarditis is rare, and worth the risk because COVID-induced myocarditis is much more prevalent.

Read More

Commentary: Tennessee Legislature Must Pass Big COVID Test in ‘Special Session’

The red state/blue state dichotomy is not simple.

Nowhere is that more apparent than Tennessee where—despite having one of the most conservative electorates in the country—the leadership has been passive at best in responding to the wishes of their supporters during these days of great crisis.

Read More